Back to Search Start Over

Sepracor reports preliminary Ph II SEP-225441 results in GAD

Source :
Pharma Marketletter. March 16, 2009
Publication Year :
2009

Abstract

USA firm Sepracor has completed the analysis and validation of the preliminary results of a Phase II, 440-patient study evaluating the efficacy and safety of SEP-225441, a modified-release formulation of [...]

Details

Language :
English
ISSN :
13558501
Database :
Gale General OneFile
Journal :
Pharma Marketletter
Publication Type :
News
Accession number :
edsgcl.196446855